<DOC>
	<DOCNO>NCT01200082</DOCNO>
	<brief_summary>The investigator hypothesize extent sulfation toxic BAs urinary elimination use biomarker predict severity prognosis hepatobiliary disease . The investigator rationale project discovery biomarkers specific liver injury would provide foundation specific non-invasive tool evaluate disease prognosis , determine patient higher risk develop end-stage liver disease , determine patient high risk recurrence hepatobiliary complication liver transplant . The investigator propose follow specific aim test investigator hypothesis : Specific Aim # 1 : Establish baseline individual total urinary BAs BA-sulfates healthy control patient hepatobiliary disease . A baseline reference average distribution percentage urinary BA-sulfates determine healthy subject patient hepatobiliary disease include chronic hepatitis C/B , alcoholic liver disease , hereditary , drug-induced , autoimmune hepatobiliary disease . The investigator work hypothesis patient ' capability sulfate total specific BAs , determine percentage total specific BAs excrete sulfate form , predict severity hepatobiliary disease , determine mayo model end-stage liver disease ( MELD ) score compensation status ( compensate decompensated ) . Patients high MELD score consider high risk develop severe hepatobiliary complication . Specific Aim # 2 : Determine relationship BA sulfation progression hepatobiliary disease . This exploratory aim collect preliminary data relationship urinary BAs progression hepatobiliary disease liver-transplant non-liver-transplant patient , monitor a1-year period . The investigator work hypothesis patient ' capability sulfate BAs determine progression disease . Patients liver transplant list continuously monitor hospitalization schedule follow-up visit 12 month release post-surgery . Disease progression evaluate monitoring MELD score , survival , incidence liver transplant , incidence complication related hepatobiliary condition fluid retention , GI bleeding , encephalopathy , biliary stricture complication .</brief_summary>
	<brief_title>Sulfation Bile Acids Biomarker Hepatobiliary Diseases</brief_title>
	<detailed_description />
	<criteria>Healthy Controls Male female , age 1965 , apparent sign hepatobiliary disease Levels high 50 , 56 , 78 U/L ALT , AST , GGT , respectively . Patient Population Male female , age 1865 , visit UNMC hepatology clinic treatment hepatobiliary disease MELD score less 6</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>chronic hepatitis C/B</keyword>
	<keyword>alcoholic liver disease</keyword>
	<keyword>primary biliary cirrhosis</keyword>
	<keyword>primary sclerosing cholangitis</keyword>
	<keyword>progressive familial intrahepatic cholestasis</keyword>
</DOC>